Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol , No 18S ( Supplement), :
© 2008 American Society of Clinical Oncology

Return to article

GEM/CDDP plus CETUXIMAB Treatment cycles (median, range) PR (95%CI) 3 (8%) 6 (16%) PR+SD (95%CI) 20 (54%) 28 (75%) TTP (median, months) 5 5 Grade 3–4 toxicities 31% 29%

Return to article